Global Information
회사소개 | 문의 | 비교리스트

폐렴간균 감염증 : 파이프라인 리뷰

Klebsiella pneumoniae Infections - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 251627
페이지 정보 영문 128 Pages
가격
US $ 2,000 ₩ 2,390,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,781,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,172,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


폐렴간균 감염증 : 파이프라인 리뷰 Klebsiella pneumoniae Infections - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 128 Pages

폐렴간균은 그램음성균이며, 폐렴간균 감염증은 균이 폐에 침투하여 발생합니다. 이 감염증은 당뇨병이나 만성 폐질환, 만성 알코올 중독 등 기초 질환을 가진 환자에서 자주 보이며, 대체로 면역 체계가 약해진 입원 환자에서 원내감염에 의해 발병합니다. 괴사, 염증, 출혈, 오한, 고열, 두통, 가슴 통증 등의 증상이 있으며, 치료법으로는 항생제 사용과 위생적인 생활 등이 있습니다.

세계의 폐렴간균 감염증(Klebsiella pneumoniae Infections) 치료제 파이프라인에 대해 조사 분석했으며, 현재의 개발 파이프라인 상황과 최신 동향, 치료제 개요, 주요 기업 및 개발중인 제품 리뷰 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

폐렴간균 감염증 개요

치료제 개발

  • 폐렴간균 감염증용 파이프라인 제품 : 개요
  • 기업별 파이프라인 제품
  • 대학/연구기관별 파이프라인 제품
  • 기업에서 개발중인 제품
  • 대학/연구기관에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

폐렴간균 감염증 : 치료제 개발 참여 기업

  • Appili Therapeutics
  • Cellceutix Corp
  • Debiopharm International SA
  • Evaxion Biotech ApS
  • F. Hoffmann-La Roche Ltd
  • FOB Synthesis Inc
  • ImmunoClin Corp
  • Kyorin Pharmaceutical Co Ltd
  • Melinta Therapeutics Inc
  • Nosopharm SAS
  • Peptilogics Inc
  • Pfizer Inc
  • Phico Therapeutics Ltd
  • Sarepta Therapeutics Inc
  • Shionogi & Co., Ltd.
  • Soligenix Inc
  • Syntiron LLC
  • Tetraphase Pharmaceuticals Inc

약제 개요

휴지중인 프로젝트

개발 중지 제품

제품 개발 마일스톤

  • 주목 뉴스 및 프레스 릴리스

부록

도표

LSH 17.06.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by ABAC Therapeutics SA, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Acies Bio doo, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by AEON Medix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Affinivax Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Appili Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by BB200 LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Bugworks Research India Pvt Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Celdara Medical LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by ContraFect Corp, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Debiopharm International SA, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Eligochem Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by EnBiotix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Fedora Pharmaceuticals Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Forge Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Melinta Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Microbiotix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Neoculi Pty Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Nosopharm SAS, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Oryn Therapeutics, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Peptilogics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Phico Therapeutics Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by ReAlta Life Sciences Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by RemAb Therapeutics SL, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Shionogi & Co Ltd, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Soligenix Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Spero Therapeutics Inc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Summit Therapeutics Plc, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Syntiron LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by VaxNewMO LLC, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Vaxxilon AG, H1 2020
  • Klebsiella pneumoniae Infections - Pipeline by Venus Medicine Research Center, H1 2020
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2020
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Klebsiella pneumoniae Infections - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Klebsiella pneumoniae Infections - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Klebsiella pneumoniae Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical and Discovery stages are 1, 27 and 12 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 6 and 2 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Klebsiella pneumoniae Infections - Overview
  • Klebsiella pneumoniae Infections - Therapeutics Development
  • Klebsiella pneumoniae Infections - Therapeutics Assessment
  • Klebsiella pneumoniae Infections - Companies Involved in Therapeutics Development
  • Klebsiella pneumoniae Infections - Drug Profiles
  • Klebsiella pneumoniae Infections - Dormant Projects
  • Klebsiella pneumoniae Infections - Discontinued Products
  • Klebsiella pneumoniae Infections - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q